0.0368 -0.022 (-37.84%) | 03-28 15:32 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 0.31 | 1-year : | 0.49 |
Resists | First : | 0.27 | Second : | 0.41 |
Pivot price | 0.31 | |||
Supports | First : | 0.03 | Second : | 0.02 |
MAs | MA(5) : | 0.23 | MA(20) : | 0.32 |
MA(100) : | 0.35 | MA(250) : | 0.97 | |
MACD | MACD : | -0.1 | Signal : | -0.1 |
%K %D | K(14,3) : | 10.7 | D(3) : | 23.8 |
RSI | RSI(14): 21.1 | |||
52-week | High : | 2.5 | Low : | 0.03 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GMDA ] has closed below the lower bollinger band by 14.6%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ GMDA ] is to continue within current trading range. It is unclear right now based on current values. 116.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 0.08 - 0.08 | 0.08 - 0.08 |
Low: | 0.05 - 0.05 | 0.05 - 0.05 |
Close: | 0.06 - 0.06 | 0.06 - 0.06 |
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Thu, 28 Mar 2024
Gamida Cell Ltd (GMDA) Stock Decreases -90.00% This Week; Should You Buy? - InvestorsObserver
Wed, 27 Mar 2024
Crude Oil Edges Lower; PaySign Shares Spike Higher - Gamida Cell (NASDAQ:GMDA), Direct Digital Holdings ( - Benzinga
Wed, 27 Mar 2024
Gamida Cell to delist as Highbridge takes full ownership - Globes
Wed, 27 Mar 2024
Gamida Cell Ltd. (GMDA) Q4 2023 Earnings Call Transcript - Seeking Alpha
Wed, 27 Mar 2024
Why Gamida Cell Shares Are Falling Today - TradingView
Wed, 27 Mar 2024
Gamida Cell Ltd. Announces Strategic Restructuring and Privatization - TipRanks.com - TipRanks
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | -54 (M) |
Shares Float | 0 (M) |
Held by Insiders | 1.3264e+008 (%) |
Held by Institutions | 1.2038e+008 (%) |
Shares Short | 0 (K) |
Shares Short P.Month | 0 (K) |
EPS | 0 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -0.82 |
Profit Margin | 0 % |
Operating Margin | -2 % |
Return on Assets (ttm) | 680.2 % |
Return on Equity (ttm) | -41.5 % |
Qtrly Rev. Growth | 103.7 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -0.58 |
Qtrly Earnings Growth | -7.591e+007 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | 0 |
PEG Ratio | 0 |
Price to Book value | -0.05 |
Price to Sales | 0 |
Price to Cash Flow | 0 |
Dividend | 9.98e+006 |
Forward Dividend | 8.86e+006 |
Dividend Yield | 28192100000% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |